The Westaim Corporation, the Toronto Stock Exchange-listed parent of de novo annuity insurer Ceres Life Insurance Company and asset manager Arena Investors, reported a net loss of $81.5 million for the second quarter of 2026, against a $0.2 million loss in the same quarter last year. The loss followed a $33.4 million net loss in the first quarter of 2026, meaning Westaim's quarterly losses have widened substantially even as the underlying insurance business continues adding premium at pace.
Ceres Life generated $303 million in premiums during the quarter, with more than $660 million issued or pending through the end of July, and grew its invested asset base to $445 million. The insurance segment nonetheless posted an adjusted EBITDA loss of $65 million for the quarter, driven primarily by a $56.8 million reserve recognised on new policies issued during the period.
Cameron MacDonald, Westaim's chief executive, framed the growth as evidence the platform is scaling as intended. "We continue to experience solid support from our national distribution partners," MacDonald said, pointing to Ceres' AI-native technology platform, which the company says can automate 85% of operations as volume increases - a claim not yet tested at the scale the business is now reaching, and one management has said September's investor day will begin to illuminate more fully.
The loss itself stems largely from an accounting mechanic rather than an operating shortfall. Under IFRS 17, the international accounting standard for insurance contracts that Westaim reports under as a Canadian-listed company, insurers must recognise reserves for future policyholder obligations at the time a policy is issued rather than spreading that recognition over the life of the contract. This treatment differs from US GAAP and produces upfront paper losses on new business even when the underlying policies are priced to be profitable over time. The faster Ceres grows premium, the larger the accounting reserve - and therefore the reported loss - becomes in the near term.
Ceres added $15.1 million in multi-year guaranteed annuity premiums and $288.1 million in fixed indexed annuity premiums during the quarter. The company said it expects the accounting drag to ease as the in-force book grows large enough for renewal earnings to offset the reserves generated by new policy issuance.
The quarterly loss trajectory tells the story precisely. The insurance segment posted an adjusted EBITDA loss of $11.6 million in Q4 2025, when the business had issued 275 MYGA policies for $40 million in total premiums. That loss climbed to $20.1 million in Q1 2026 and now stands at $65 million for Q2 - tracking closely with the rapid acceleration in new premium volume each quarter. The accounting loss is large because the new business is large, not because individual policies are underperforming.
Alongside the results, Westaim announced that Deanna Mulligan, Ceres Life's founding chief executive, will move into a strategic advisor role, with chief legal officer Erik Askelsen stepping up to president and acting CEO. Mulligan, a former CEO and chair of Guardian Life Insurance Company of America, led Ceres Life from its 2015 founding through the 2025 launch of its multi-year guaranteed annuity product and this year's rollout of its fixed indexed annuity offering.
Askelsen joined Ceres in March 2025 as chief legal officer after previous roles as chief legal officer of American Equity and general counsel of Athene and Aviva USA - three of the most significant fixed annuity carriers in the US market. That credential set is directly relevant to a business distributing fixed annuity products at scale and managing the legal, compliance and regulatory relationships that come with it.
Chinh Chu, Westaim's executive chairman, said Mulligan had been instrumental in building the company's foundation - assembling the team, the technology and the risk framework the business runs on today.
For annuity distribution partners, reinsurers and rating agencies watching de novo platforms at this stage, two questions matter most heading into Westaim's September investor day. The first is the IFRS 17 accounting dynamic the results reflect: as long as premium growth continues at pace, accounting losses will continue growing alongside it, and that trajectory is an expected feature of the business model, not a warning sign. The second - and the one that will ultimately determine whether those paper losses eventually resolve into profitability - is whether Ceres Life's reserve assumptions and pricing are adequate for the policies now on the books. The invested asset base of $445 million against $660 million in issued or pending premiums gives some scale context, but the adequacy of the underlying reserves is what distribution partners with significant Ceres exposure should be asking about directly at the September investor day.
Westaim will unveil a new company name and rebrand on September 14, ahead of the September 17 investor day where management said it would provide additional detail on asset management growth, strategic partnerships and financial outlook. For distribution partners, that presentation is the first substantive opportunity to assess whether the business model's profitability trajectory holds up against the premium acceleration the Q2 results document.
